2. Signaling Pathways
  3. Apoptosis
  4. Bcl-2 Family
  5. Bcl-2 Family Isoform
  6. Bcl-2 Family Inhibitor

Bcl-2 Family Inhibitor

Bcl-2 Family Inhibitors (199):

Cat. No. Product Name Effect Purity
  • HY-163764
    Bfl-1-IN-4
    		Inhibitor
    Bfl-1-IN-4 (Compound 8) is an inhibitor for Bcl-2 associated protein A1 (Bfl-1) with an IC50 of 16.8 μM.
  • HY-12048R
    Chelerythrine chloride (Standard)
    		Inhibitor
    Chelerythrine (chloride) (Standard) is the analytical standard of Chelerythrine (chloride). This product is intended for research and analytical applications. Chelerythrine chloride is a potent, cell-permeable inhibitor of protein kinase C, with an IC50 of 660 nM. Chelerythrine chloride inhibits the Bcl-XL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine chloride induces apoptosis and autophagy.
  • HY-149625
    Bcl-2-IN-15
    		Inhibitor
    Bcl-2-IN-15 (Compound 13d)) is a Bcl-2 inhibitor (IC50: 363 nM). Bcl-2-IN-15 inhibits the proliferation ofNCI leukemia cancer cell line.
  • HY-163309
    Bcl-2-IN-19
    		Inhibitor
    Bcl-2-IN-19 (compound 27) is a potent Bcl-2 inhibitor for targeting breast cancer.
  • HY-RS01374
    BAX Human Pre-designed siRNA Set A
    		Inhibitor

    BAX Human Pre-designed siRNA Set A contains three designed siRNAs for BAX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
  • HY-172262
    WEHI-3773
    		Inhibitor
    WEHI-3773 is an inhibitor of the interaction between VDAC2 and BAK or BAX. WEHI-3773 inhibits BAX-mediated Apoptosis by blocking the VDAC2-mediated recruitment of BAX to mitochondria. Conversely, WEHI-3773 promotes BAK-mediated Apoptosis by limiting the inhibitory sequestration of BAK by VDAC2. WEHI-3773 is promising for research in the field of anti-cancer .
  • HY-N13869
    Asperlin
    		Inhibitor
    Asperlin is an orally active marine-derived antibiotic with antifungal, anticancer, anti-inflammatory and anti-atherosclerotic activities. Asperlin induces apoptosis. Asperlin increases reactive oxygen species (ROS)- and DNA damage-associated G2/M phase arrest and ATM phosphorylation. Asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota.
  • HY-N2897R
    Dihydrokaempferol (Standard)
    		Inhibitor
    Dihydrokaempferol (Standard) is the analytical standard of Dihydrokaempferol. This product is intended for research and analytical applications. Dihydrokaempferol is isolated from Bauhinia championii (Benth). Dihydrokaempferol induces apoptosis and inhibits Bcl-2 and Bcl-xL expression. Dihydrokaempferol is a good candidate for new antiarthritic agents.
  • HY-127057
    Lambertianic acid
    		Inhibitor
    Lambertianic acid is a bioactive diterpene with anti-allergic, antibacterial and anticancer activities. Lambertianic acid decreases androgen receptor protein levels, cellular and secretory levels of prostate-specific antigen. Lambertianic acid also suppresses cell proliferation by inducing G1 arrest, downregulating CDK4/6 and cyclin D1, activating p53, p21 and p27. Lambertianic acid induces Apoptosis and the expression of related proteins, including cleaved caspase-3/9, c-PARP and BAX, and inhibited BCl-2. Lambertianic acid is promising for research of prostate cancer.
  • HY-101083A
    (Rac)-BDA-366
    		Inhibitor
    (Rac)-BDA-366 (example 2) is the despinner of BDA-366 (HY-101083). BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells.
  • HY-12011A
    (Rac)-HA14-1
    		Inhibitor
    (Rac)-HA14-1 is the racemic form of HA14-1 (HY-12011). HA14-1 is a Bcl-2/Bcl-xL antagonist with an IC50 of approximately 9 μM against Bcl-2.
  • HY-164468
    Ch282-5
    		Inhibitor
    Ch282-5 is an orally active inhibitor targeting the Bcl-2 protein, inducing mitochondria-dependent apoptosis (Apoptosis) by disrupting mitophagy and the mTOR pathway. Ch282-5 exhibits antiproliferative activity against colorectal cancer cells both in vitro and in vivo, and it also inhibits metastasis. Additionally, Ch282-5 enhances Oxaliplatin (HY-17371)-induced autophagy (Autophagy) by downregulating the Mcl-1 protein and increasing platelet count, alleviating adverse effects of Navitoclax (HY-10087).
  • HY-N15378
    β-Carotene-15,15'-epoxide
    		Inhibitor
    β-carotene-15,15ʹ-epoxide is a XIAP antagonist with apoptosis-inducing and antitumor activity, found in the leaves of Spondias mombin. In a DMBA (HY-W011845)-induced rat model of breast cancer, β-carotene-15,15ʹ-epoxide binds to the BIR3 domain of the anti-apoptotic protein XIAP, blocking its interaction with caspase-9 and thereby promoting tumor cell apoptosis. In addition, β-carotene-15,15ʹ-epoxide significantly downregulates the expression of BCL-2, COX-2, and TNF-α in tumor tissues, reduces MDA levels, increases catalase activity, and modulates serum levels of LDH, ALP, and ALT, demonstrating strong antioxidant, anti-inflammatory, and metabolic protective effects. β-carotene-15,15ʹ-epoxide may be used in research on inflammation-related conditions and cancers such as breast cancer.
  • HY-10087R
    Navitoclax (Standard)
    		Inhibitor
    Navitoclax (Standard) is the analytical standard of Navitoclax. This product is intended for research and analytical applications. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM[1].
  • HY-15531S1
    Venetoclax-d6
    		Inhibitor
    Venetoclax-d6 (ABT-199-d6) is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy.
  • HY-165537
    Siphonaxanthin
    		Inhibitor
    Siphonaxanthin is a keto-carotenoid with anti-angiogenic activity, which is found in green algae. Siphonaxanthin targets death receptor 5 (DR5) and induces apoptosis in cancer cells. Siphonaxanthin upregulates the expression of DR5, decreases the expression of Bcl-2, and activates caspase-3 in human leukemia HL-60 cells. Siphonaxanthin is an inhibitor of fibroblast growth factor receptor-1 (FGFR-1) signaling transduction in vascular endothelial cells. Siphonaxanthin inhibits the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs), as well as the outgrowth of microvessels in the rat aortic ring. Siphonaxanthin can also inhibit the translocation of the high-affinity IgE receptor (FcεRI) to lipid rafts in mast cells, acting as an anti-inflammatory agent. Siphonaxanthin is promising for research of diseases such as cancer, diabetic retinopathy, and rheumatoid arthritis.
  • HY-B2046R
    Simazine (Standard)
    		Inhibitor
    Simazine (Standard) is the analytical standard of Simazine (HY-B2046). This product is intended for research and analytical applications. Simazine is a triazine herbicide. Simazine is widely used in agriculture, potted plant and tree production. In addition, Simazine can induce the apoptosis of immune cells in the spleen of mice and inhibit the proliferation of B cells and T cells in mice.
  • HY-103243R
    TCPOBOP (Standard)
    		Inhibitor
    TCPOBOP (Standard) is the analytical standard of TCPOBOP. This product is intended for research and analytical applications. TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss[1]. TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins[2].
  • HY-B1839R
    Fluazinam (Standard)
    		Inhibitor
    Fluazinam (Standard) is the analytical standard of Fluazinam (HY-B1839). This product is intended for research and analytical applications. Fluazinam is a broad spectrum pyridinamine fungal inhibitor. Fluazinam is an orally active dinitroaniline fungicide. Fluazinam induces phosphorylation of JNK, activates p38 pathway, decreases Bcl-2, activates caspase-3, decreases complex I activity, increases Autophagy and Apoptosis. Fluazinam has strong antifungal activity against F. fujikuroi and B. maydis. Fluazinam has a negative impact on Brachydanio rerio and worker bees.